The ‘Denial Engine’: HHS Report Reveals Shocking Prior Authorization Rates in Medicare Advantage
Table of Contents
The Algorithm of Denial
In the complex machinery of American healthcare, ‘prior authorization’ is often framed by insurers as a quality-control mechanism—a way to ensure patients receive the right care at the right time. However, a new report from the Department of Health and Human Services (HHS) Office of the Inspector General (OIG) suggests that for millions of Medicare Advantage patients, the process functions less like a safety check and more like a financial barrier.
The findings are stark: some of the nation’s largest private Medicare Advantage plans are denying requests for rehabilitation and other critical services at staggering rates. In some instances, the denial rate for long-term care reached as high as 80%, creating a massive disparity in how care is accessed based solely on which insurer a patient uses.
For the nearly 20 million people enrolled in plans managed by the industry’s three largest players—UnitedHealthcare, CVS Health (Aetna), and Humana—these statistics translate to real-world delays in recovering from strokes, heart attacks, and severe fractures. According to the OIG, these three companies saw some of the highest denial rates, with certain requests rejected more than 70% of the time.
The ‘Overturn’ Paradox
Perhaps the most damning evidence of a systemic failure is not the initial denial, but what happens afterward. A second report released alongside the primary findings focused on skilled nursing facility care. It revealed a paradoxical trend: when patients appealed these denials, the plans reversed their decision 95% of the time.
“We’re looking at an extremely high overturn rate,” said Rosemary Bartholomew, the lead author of the reports. This suggests that the initial denials were not based on a lack of medical necessity, but were instead a systemic failure at the first request step—effectively a gamble by insurers that most patients would not bother to appeal.
Miranda Yaver, an assistant professor of health policy and management at the University of Pittsburgh, argues that this pattern points toward a profit-driven motive. Because Medicare Advantage plans receive a fixed government payment per patient, any cost avoided—even through the denial of necessary care—directly pads the bottom line. “It’s hard to see cost as being divorced from the calculations about coverage,” Yaver noted, emphasizing that for-profit insurers showed significantly higher denial rates than nonprofit counterparts.
Administrative Friction vs. Medical Necessity
The insurance industry has long defended prior authorization as a tool to prevent unnecessary procedures and curb skyrocketing healthcare costs. In an emailed statement, Aetna (CVS Health) maintained that they “review requests promptly” and offer a “clear appeals process.” Some analysts, including Meredith Freed of the nonpartisan health policy group KFF, suggest that some denials stem from administrative friction—doctors submitting incorrect billing codes or missing documentation.
However, the scale of the disparities found in the HHS report largely undercuts the ‘administrative error’ defense. When one company denies 8% of requests and another denies 80% for the same service, the variable is no longer the provider’s paperwork—it is the insurer’s internal policy.
The financial stakes are immense. The report notes that long-term acute care hospital stays averaged roughly $49,000 in 2023, while inpatient rehabilitation facilities cost approximately $24,000. By denying these high-ticket services, insurers effectively shift the financial burden to the patient or force them into lower-quality care environments.
Pressure for Regulatory Oversight
The report comes at a time of intense political scrutiny. Health Secretary Robert F. Kennedy Jr. has pledged to reform the prior authorization process, citing a need to streamline rules and reduce the number of services requiring preapproval. While industry groups like AHIP claim that leading plans have already eliminated 11% of authorizations across various medical services, experts warn that these voluntary reductions are a drop in the bucket compared to the systemic issues identified by the OIG.
To combat this lack of transparency, the OIG is now recommending that the Centers for Medicare & Medicaid Services (CMS) implement more rigorous and regular data collection on prior authorization. Currently, the government lacks the granular visibility needed to track these rates in real-time, allowing insurers to operate their approval algorithms in a virtual black box.
As the OIG pushes for more oversight, the central question remains whether the ‘prior authorization’ model can ever be truly patient-centered, or if it will continue to serve as a primary tool for margin expansion in the private insurance market.
